US equities |
NVDA $238.44 ▲+1.92% SPCX $167.43 ▲+5.33% MU $1,062.95 ▼-1.11% TSLA $380.31 ▲+2.62% MSFT $525.46 ▲+1.53% SNDK $1,709.11 ▼-0.63% INTC $117.06 ▼-1.90% META $743.23 ▲+2.08%
FinancialContent

Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

5.990 +0.120 (+2.04%)
Delayed Quote Updated: 2:27 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytek Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
Cytek’s Cutting-Edge Spectral Flow Cytometry Technology, Specialized Staff, Tools and Solutions Set New Benchmarks for Cell Analysis 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for Cytek Biosciences ↗
 
Via Benzinga
News headline image
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
New System Saves Time and Resources, Improves Efficiency and Accuracy 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market, Bullish Analyst Says ↗
Stephens initiated coverage on Cytek Biosciences Inc (NASDAQ: CTKB), a manufacturer and supplier of flow cytometry products and services.  
Via Benzinga
Topics Supply Chain
News headline image
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Cytek Biosciences Reports Third Quarter 2023 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Morgan Stanley Maintains Equal-Weight Rating for Cytek Biosciences: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Cytek Biosciences to Report Third Quarter 2023 Financial Results on November 7, 2023
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. 
Via Benzinga
News headline image
Wyndham Hotels & Resorts, Olink Holding And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational and Clinical Markets in the United States 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and Europe
Company to Lead Symposiums at ICCS and ESCCA 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Launches Educational Roadshow Focused on Spectral Flow Cytometry
The Cytek Reveal Roadshow Will Provide Insights to Accelerate Discoveries – from Basic Science to Highly Complex Assays 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services
Sales Organization Enhanced, Platform Organization Created 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Participate in the UBS MedTech, Tools and Genomics Summit
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences Reports Second Quarter 2023 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Participate in the 44th Annual Goldman Sachs Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >